ResearchSafe

Is the hype around PE 22-28 getting ahead of the actual science?

Posted by data_swims in Research & News - 45 points, 4 comments.

I was reading up on some of the latest preclinical stuff regarding PE 22-28 lately and it really got me thinking about how we talk about neuroplasticity in these circles. It is a spadin derived peptide that targets those TREK-1 potassium channels to try and boost serotonin signaling and synaptogenesis, and the idea of a fast acting antidepressant that works way quicker than the old school SSRIs is obviously super appealing for anyone interested in cognitive health.

But I kind of feel like the community gets a little ahead of itself sometimes with these compounds. For me, it feels like we see these animal models or early bench research and immediately start looking for ways to integrate it into a stack, but we really have no idea about the human safety profile or how the half life actually plays out in a person. It is a huge jump from showing neurogenesis in a lab setting to actually helping a human with mood regulation without causing some weird side effect we haven't even mapped out yet.

Does anyone else feel like we should be more skeptical of these fast acting neuroplasticity agents until we see more actual human data?

Comments

  • miles_codes: You are spot on. The jump from rodent models to human neurochemistry is massive. A lot of the hype in these forums feels like it is fueled by the excitement of a new mechanism rather than actual clinical reality. I have seen this cycle before with other neuroactive compounds. People get blinded by the idea of fast acting results. For me, the biggest concern is always the long term effect on those potassium channels. If you are messing with synaptogenesis, you are playing with the very wiring of
  • formernico: For what it is worth, I agree. That leap from mice to humans is where things usually fall apart. I tend to get a bit nervous thinking about those TREK-1 channels too. If you mess with the baseline electrical signaling in the brain, you might be fixin' to deal with some weird side effects down the road. I'm staying skeptical until human data shows up.
  • data_swims: I think you hit the nail on the head with the electrical signaling part. That's exactly what worries me because if those TREK-1 channels are responsible for maintaining the resting membrane potential (and keeping things stable), messing with them could potentially mess with everything else. It is a fine line between boosting signaling and just creating noise. Do you think there is a specific type of human trial we should be looking for to ease that concern, or is it just a wait and see game for
  • data_swims: That part about the wiring of the brain is exactly what worries me, and it is a bit scary to think about potentially changing things permanently without a map. I have always been a bit cautious with stuff that hits the potassium channels (since we know how touchy those can be) and it just seems like a gamble. Do you think the risk is higher with these peptides compared to the older nootropics we usually see?

Community discussion - research and educational context only. Not medical advice.